BridgeMD
New treatment option for Rotator Cuff Disease
Official title Arthroscopic Rotator Cuff Repair with UC-MSCs for Large to Massive Tears
ClinicalTrials.gov ID: NCT06817616
What this study is testing
What is Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell?
Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for rotator cuff disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Safety Analysis of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients Undergoing Rotator Cuff Repair for Massive or Large Rotator Cuff Tears
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 and older
You may be able to join if
- Male or female 19 years of age and older
- Unilateral shoulder pain with a pain score of 4 or higher.
- patients with a symptom duration of at least three months who have not responded to conventional treatments, including analgesics.
- patients diagnosed with massive or extensive full-thickness rotator cuff tears confirmed by computed tomography arthrography or magnetic resonance...
You likely can't join if
- patients diagnosed with small or medium full-thickness rotator cuff tears among study participants with full-thickness rotator cuff tears.
- patients who have received subacromial injection therapy in the affected shoulder within the past three months.
- patients who have undergone rotator cuff surgery on the affected shoulder within the past six months.
- patients exhibiting or suspected of having the following radiological findings: malignant tumors, severe glenohumeral osteoarthritis, or bony...
- patients presenting with symptomatic cervical spine disorders.
- patients experiencing bilateral shoulder pain.
See the full eligibility criteria
- Male or female 19 years of age and older
- Unilateral shoulder pain with a pain score of 4 or higher.
- patients with a symptom duration of at least three months who have not responded to conventional treatments, including analgesics.
- patients diagnosed with massive or extensive full-thickness rotator cuff tears confirmed by computed tomography arthrography or magnetic resonance imaging.
- patients diagnosed with small or medium full-thickness rotator cuff tears among study participants with full-thickness rotator cuff tears.
- patients who have received subacromial injection therapy in the affected shoulder within the past three months.
- patients who have undergone rotator cuff surgery on the affected shoulder within the past six months.
- patients exhibiting or suspected of having the following radiological findings: malignant tumors, severe glenohumeral osteoarthritis, or bony abnormalities causing subacromial space narrowing.
- patients presenting with symptomatic cervical spine disorders.
- patients experiencing bilateral shoulder pain.
- patients diagnosed with multiple arthritis, infectious arthritis, rheumatoid arthritis, or fibromyalgia.
- patients with neurological deficits.
- Pregnant or breastfeeding patients
- patients unwilling to use effective contraception during the study period.
- patients currently infected with HBV, HCV, or HIV, or those with a positive RPR test result.
- patients with severe conditions that may affect the study, including cardiovascular diseases, renal diseases, hepatic diseases, endocrine disorders, or malignancies.
- patients who are unable to comprehend the questionnaires used for study assessments, including the Visual Analog Scale (VAS), or those with communication difficulties due to psychiatric disorders.
- Any other cases deemed inappropriate for study participation by the investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Seoul, Korea, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Seoul, Korea, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.